Concepedia

Matthew L. Sherman

ML

Statistics

Publications

83

Citations

10.4K

H-Index

45

Active since

1984

Affiliations

Dana-Farber Cancer Institute(Current)

Acceleron Pharma (United States)

Harvard University

Memorial Sloan Kettering Cancer Center

Deciphera Pharmaceuticals (United States)

Matthew L. Sherman is an author at Dana-Farber Cancer Institute specializing in medicine, immunology, and cell biology.

Top concepts

Publications per year

1984–2024

83

Publications

83

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

Michael B. Atkins, Manuel Hidalgo, Walter M. Stadler et al. · Journal of Clinical Oncology · 2004 · 943 citations · Full text

, , +15

Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

Eric L. Sievers, Richard A. Larson, Edward A. Stadtmauer et al. · Journal of Clinical Oncology · 2001 · 882 citations

Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.

John P. Leonard, Matthew L. Sherman, Gerald L. Fisher et al. · PubMed · 1997 · 811 citations

Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.

Michael B. Atkins, Michael J. Robertson, Michael S. Gordon et al. · PubMed · 1997 · 590 citations

, , +19

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti et al. · New England Journal of Medicine · 2020 · 519 citations · Full text

Rows per page

1–5 of 83